Guided Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $22.2M
- Price
- $0.2299
- % Change (Daily % change from the live per-ticker quote feed.)
- +13.81%
- Volume
- 15.0K
About
Guided Therapeutics, Inc. is a medical technology firm specializing in the creation of medical devices. Its primary focus is on bringing to market LuViva, an innovative device designed for the non-invasive detection of cervical cancer. This technology excels at identifying both cancerous and precancerous conditions of the cervix in a painless, non-invasive manner, directly at the point of care. LuViva operates by scanning the cervix with light and subsequently analyzing both the reflected and fluorescent light emitted. Established in 1992 and headquartered in Norcross, Georgia, the company was formerly known as SpectRx, Inc. until its rebranding to Guided Therapeutics, Inc. in February 2008.
Quick stats
Shares outstanding96.5M
Computed float36.9M
Float / shares38.3%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000924515
Websitehttps://www.guidedinc.com
AI Summary
AI-generated1/6
majorbullishpartnership
Guided Therapeutics Reaches Collaborative Agreement with Türkiye’s Ministry of Health to Become Primary Screening Test for Cervical Cancer
Guided Therapeutics has reached a collaborative agreement with Türkiye's Ministry of Health to co-develop its LuViva Advanced Cervical Scan for primary screening of cervical cancer in Türkiye.
The first step is a six-month, 800-patient clinical study beginning enrollment this month, funded by the Ministry of Health — including purchases of LuViva devices and single-use Cervical Guides — to optimize LuViva's AI pattern recognition algorithms for real-time detection of early cellular changes.
If the study succeeds, LuViva could potentially be used to screen up to 20 million Turkish women annually, a country-scale deployment opportunity for the OTCQB micro-cap.
Near-term revenue is limited to study-related device purchases, and LuViva remains investigational in the U.S., so the payoff hinges on study outcomes and any subsequent deployment decision.
Red flags
- LuViva is limited by federal law to investigational use in the U.S. — no FDA commercial approval domestically
- Forward-looking statements explicitly cite going-concern uncertainty ('the uncertainty of future capital to develop products or continue as a going concern')
- No financial terms disclosed; national screening upside is entirely contingent on a successful six-month study outcome